- Home
- SHOT vs GDTC Comparison
SHOT vs GDTC Comparison
Compare SHOT & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- GDTC
- Stock Information
- Founded
- SHOT 2018
- GDTC 2018
- Country
- SHOT United States
- GDTC Singapore
- Employees
- SHOT N/A
- GDTC N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- SHOT Health Care
- GDTC Health Care
- Exchange
- SHOT Nasdaq
- GDTC Nasdaq
- Market Cap
- SHOT 30.4M
- GDTC 28.0M
- IPO Year
- SHOT 2020
- GDTC 2023
- Fundamental
- Price
- SHOT $0.31
- GDTC $2.28
- Analyst Decision
- SHOT
- GDTC Buy
- Analyst Count
- SHOT 0
- GDTC 1
- Target Price
- SHOT N/A
- GDTC $5.00
- AVG Volume (30 Days)
- SHOT 7.1M
- GDTC 10.1K
- Earning Date
- SHOT 08-13-2025
- GDTC 01-01-0001
- Dividend Yield
- SHOT N/A
- GDTC N/A
- EPS Growth
- SHOT N/A
- GDTC N/A
- EPS
- SHOT N/A
- GDTC N/A
- Revenue
- SHOT $573,336.00
- GDTC $368,838.00
- Revenue This Year
- SHOT N/A
- GDTC $5.37
- Revenue Next Year
- SHOT N/A
- GDTC N/A
- P/E Ratio
- SHOT N/A
- GDTC N/A
- Revenue Growth
- SHOT 69.32
- GDTC N/A
- 52 Week Low
- SHOT $0.23
- GDTC $1.20
- 52 Week High
- SHOT $1.77
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- SHOT 47.00
- GDTC 57.60
- Support Level
- SHOT $0.23
- GDTC $2.04
- Resistance Level
- SHOT $0.37
- GDTC $2.14
- Average True Range (ATR)
- SHOT 0.05
- GDTC 0.06
- MACD
- SHOT 0.01
- GDTC 0.02
- Stochastic Oscillator
- SHOT 40.84
- GDTC 91.67
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.